Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

Sotorasib targets the KRAS G12C protein specifically and is the first KRAS G12C inhibitor to be FDA-approved for clinical use. It works by binding to the mutated KRAS G12C protein, blocking its ...

The new study, conducted with support from Amgen Inc., builds on previous research by Dr. Fakih’s team that found sotorasib could be made more effective when combined with panitumumab.

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new City of Hope ...

The new study builds on previous research by Dr. Fakih's team showing that sotorasib could be made more effective when combined with panitumumab. City of Hope is a national leader in working ...

The new study, conducted with support from Amgen Inc., builds on previous research by Dr. Fakih’s team that found sotorasib could be made more effective when combined with panitumumab.

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new City of Hope ...

In a study published in the Journal of Clinical Oncology, colorectal cancer patients who received a combination of two drugs, the small-molecule KRAS G12C inhibitor sotorasib combined with the ...